دورية أكاديمية
Transcatheter Mitral Valve-in-Valve Implantation with the Balloon-Expandable Myval Device
| العنوان: | Transcatheter Mitral Valve-in-Valve Implantation with the Balloon-Expandable Myval Device |
|---|---|
| المؤلفون: | Sara Blasco-Turrión, Ana Serrador-Frutos, John Jose, Gunasekaran Sengotuvelu, Ashok Seth, Victor G. Aldana, Juan Pablo Sánchez-Luna, Jose Carlos Gonzalez-Gutiérrez, Mario García-Gómez, Javier Gómez-Herrero, Cristhian Aristizabal, J. Alberto San Román, Ignacio J. Amat-Santos |
| المصدر: | Journal of Clinical Medicine, Vol 11, Iss 17, p 5210 (2022) |
| بيانات النشر: | MDPI AG, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Medicine |
| مصطلحات موضوعية: | valve-in-valve, mitral bioprosthesis, TMVR, Myval, Sapien, Medicine |
| الوصف: | Background: The vast majority of transcatheter valve-in-valve (ViV) mitral procedures have been reported with the SAPIEN family. We aimed to report the preliminary experience with the Myval balloon-expandable device in this setting. Methods: Multicenter retrospective study of high-risk surgical patients with mitral bioprosthesis degeneration undergoing transcatheter ViV implantation with Myval device. Results: A total of 11 patients from five institutions were gathered between 2019 and 2022 (age 68 ± 7.8, 63% women). The peak and mean transvalvular gradients were 27 ± 5 mmHg and 14.7 ± 2.3 mmHg, respectively, and the predicted neo-left ventricular outflow tract (neo-LVOT) area was 183.4 ± 56 mm2 (range: 171 to 221 mm2). The procedures were performed via transfemoral access in all cases (through echocardiography-guided transeptal puncture (81.8% transesophageal, 11.2% intracardiac)). Technical success was achieved in all cases, with no significant residual mitral stenosis in any of them (peak 7.2 ± 2.7 and mean gradient 3.4 ± 1.7 mmHg) and no complications during the procedure. There were no data of LVOT obstruction, migration, or paravalvular leak in any case. Mean hospital stay was 3 days, with one major vascular complication and no stroke. At 6-month follow-up, there was one case with suboptimal anticoagulation presenting an increase in the transmitral gradients (mean 15 mmHg) that normalized after optimization of the anticoagulation, but no other relevant events. Conclusions: Transseptal ViV mitral implantation with the balloon-expandable Myval device was feasible and safe avoiding redo surgery in high-risk patients with bioprosthesis degeneration. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2077-0383 22629343 |
| Relation: | https://www.mdpi.com/2077-0383/11/17/5210; https://doaj.org/toc/2077-0383 |
| DOI: | 10.3390/jcm11175210 |
| URL الوصول: | https://doaj.org/article/30455c2262934312a06fed717a43b2cb |
| رقم الأكسشن: | edsdoj.30455c2262934312a06fed717a43b2cb |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 20770383 22629343 |
|---|---|
| DOI: | 10.3390/jcm11175210 |